L
Lynn E. Taylor
Researcher at Brown University
Publications - 82
Citations - 2599
Lynn E. Taylor is an academic researcher from Brown University. The author has contributed to research in topics: Hepatitis C & Hepatitis C virus. The author has an hindex of 24, co-authored 75 publications receiving 2458 citations. Previous affiliations of Lynn E. Taylor include Rhode Island Department of Corrections & Miriam Hospital.
Papers
More filters
Journal ArticleDOI
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.
TL;DR: Sofosbuvir is the first DAA indicated for use as part of an interferon-free regimen and shows response rates greater than 90%, shortened treatment duration (8 to 12 weeks), and improved tolerability and safety (although with some combinations, lower responses are seen in persons with more advanced disease and certain HCV genotypes).
Journal ArticleDOI
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
Norbert Bräu,Norbert Bräu,Rena K. Fox,Peiying Xiao,Kristen M. Marks,Zeenat Naqvi,Lynn E. Taylor,Anita Trikha,Morris Sherman,Mark S. Sulkowski,Douglas T. Dieterich,Michael O. Rigsby,Teresa L. Wright,Maria D. Hernandez,Maria D. Hernandez,Mamta K. Jain,Gajendra K. Khatri,Richard K. Sterling,Maurizio Bonacini,Catherine A. Martyn,Ayse Aytaman,Josep M. Llovet,Sheldon T. Brown,Sheldon T. Brown,Edmund J. Bini +24 more
TL;DR: HCC patients in HIV-positive HCC patients are younger and more frequently symptomatic and infected with HCV or HBV than HIV-negative patients, and tumor staging and survival are similar.
Journal ArticleDOI
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Jason Grebely,Geert Robaeys,Geert Robaeys,Philip Bruggmann,Alessio Aghemo,Markus Backmund,Julie Bruneau,Jude Byrne,Olav Dalgard,Jordan J. Feld,Margaret Hellard,Margaret Hellard,Matthew Hickman,Achim Kautz,Alain H. Litwin,Andrew R. Lloyd,Stefan Mauss,Maria Prins,Tracy Swan,Martin Schaefer,Lynn E. Taylor,Gregory J. Dore +21 more
TL;DR: It is demonstrated that treatment among PWID is feasible and provide a framework for HCV assessment and care, and further research is needed to evaluate strategies to enhance testing, linkage to care, treatment, adherence, viral cure, and prevent HCV reinfection among PWIDs.
Journal ArticleDOI
Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels
TL;DR: This review will outline barriers to HCV care in HCV/HIV coinfection, with a particular emphasis on persons who inject drugs, proposing strategies to enhance HCV treatment uptake and outcomes.
Journal ArticleDOI
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.
Barbara H. McGovern,Barbara H. McGovern,Jeremy S. Ditelberg,Jeremy S. Ditelberg,Lynn E. Taylor,Lynn E. Taylor,Rajesh T. Gandhi,Katerina A. Christopoulos,Stacey Chapman,Beth Schwartzapfel,Emily Rindler,Anne-Marie Fiorino,M. Tauheed Zaman,M. Tauheed Zaman,Paul E. Sax,Paul E. Sax,Fiona Graeme-Cook,Patricia L. Hibberd,Patricia L. Hibberd +18 more
TL;DR: In this multiracial population of HIV-HCV-coinfected patients, steatosis was prevalent and was associated with severity of liver fibrosis, and may play a contributory role in the progression of liver disease in HIV-infected patients.